ISPOR - HPR16 Comparison of Outcomes-Based Reimbursement (OBR) Schemes in Europe and the US for CAR-T Cell Therapy: Tisagenlecleucel

Full Text

HPR16 Comparison of Outcomes-Based Reimbursement (OBR) Schemes in Europe and the US for CAR-T Cell Therapy: Tisagenlecleucel

Abstract

Authors

D Lucion J Wright S Hall

Back to Volume 25, Supplemental Issue 12S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now